WHO launches Ebola treatment trial in DRC as outbreak deaths exceed 500
The World Health Organization has launched a clinical trial in the Democratic Republic of Congo to test two experimental treatments—Mapp Biopharmaceutical's monoclonal antibody MBP134 and Gilead's antiviral remdesivir—for the Bundibugyo strain of Ebola. The outbreak, centred in Ituri Province, has recorded 1,561 confirmed cases and 506 deaths, making it the largest ever for this virus strain. The adaptive platform trial will enroll several hundred patients, assigning them to MBP134, remdesivir, a combination, or optimized supportive care alone, and will track 28-day mortality, viral clearance, organ function and outcomes in pregnant women and children, groups usually excluded from such studies.
For Nigerians, the outbreak matters because Ebola could spread to neighbouring countries, disrupting trade and travel across West and Central Africa. The United Nations warns that a wider regional spread could cut Africa's economic output by up to $3.6 billion and put roughly 328,000 jobs at risk. While the current outbreak is largely confined to the DRC and Uganda, the economic ripple effects could affect commodity prices and remittance flows that many Nigerian households rely on.
What you should know: there is still no licensed vaccine or specific treatment for the Bundibugyo strain. The trial's results may shape future outbreak responses. Stay informed via official health advisories from the Nigeria Centre for Disease Control, practice good hygiene, and consider supporting reputable humanitarian organisations working on outbreak containment.